PMC 401s
Alternative Names: Anti-ANG2 antagonistic fully human ScFv - PharmAbcine; PMC-401sLatest Information Update: 02 Jan 2024
At a glance
- Originator PharmAbcine
- Class Eye disorder therapies; Immunoglobulin Fv fragments
- Mechanism of Action Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Diabetic retinopathy
Most Recent Events
- 02 Jan 2024 PMC 401s is still in preclinical trials for Age-related macular degeneration in South Korea (Parenteral) (PharmAbcine pipeline, January 2024)
- 02 Jan 2024 PMC 401s is still in preclinical trials for Diabetic retinopathy in South Korea (Parenteral) (PharmAbcine pipeline, January 2024)
- 19 Aug 2021 PharmAbcine has patent pending for an anti-ANG2 (Angiopoietin 2) antibody world wide